Last reviewed · How we verify
PN20 treatment
At a glance
| Generic name | PN20 treatment |
|---|---|
| Also known as | thrombopoietin receptor agonist |
| Sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE1, PHASE2)
- Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) (PHASE1)
- A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients (PHASE1)
- Efficacy and Safety of PN20 (Plinest) for the Improvement of Skin Hydration (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |